

Mickael Hiligsmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9228285/publications.pdf>

Version: 2024-02-01

203
papers

4,907
citations

87723

38
h-index

133063

59
g-index

211
all docs

211
docs citations

211
times ranked

5920
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. <i>Developmental Medicine and Child Neurology</i> , 2023, 65, 67-77.	1.1	20
2	Evaluating Health Related Quality of Life in Older People at Risk of Osteoporotic Fracture: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-6D. <i>Social Indicators Research</i> , 2022, 160, 809-824.	1.4	1
3	Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. <i>Patient</i> , 2022, 15, 207-218.	1.1	13
4	Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review. <i>Osteoporosis International</i> , 2022, 33, 13-26.	1.3	6
5	Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 795-803.	0.7	0
6	Health-related quality of life of patients with a recent fracture attending a fracture liaison service: a 3-year follow-up study. <i>Osteoporosis International</i> , 2022, 33, 577-588.	1.3	11
7	Mogamulizumab for Previously Treated Mycosis Fungoides and S�azary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2022, 40, 509-518.	1.7	1
8	The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 869-876.	0.7	4
9	Enhancing Public Participation in Public Health Offerings: Patient Preferences for Facilities in the Western Cape Province Using a Discrete Choice Experiment. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 590.	1.2	2
10	Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. <i>BMC Public Health</i> , 2022, 22, 46.	1.2	33
11	Identification and Prioritization of Attributes for a Discrete Choice Experiment Using the Nominal Group Technique: Patients' Choice of Public Health Facilities in Cape Town, South Africa. <i>Value in Health Regional Issues</i> , 2022, 27, 90-98.	0.5	3
12	Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. <i>Osteoporosis International</i> , 2022, , 1.	1.3	0
13	Optimising Access Surgery in Senior Haemodialysis Patients (OASIS): study protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e053108.	0.8	3
14	DISCRETE CHOICE EXPERIMENT TO INVESTIGATE PREFERENCES FOR INCENTIVES TO PROMOTE ANTIMICROBIAL RESEARCH & DEVELOPMENT. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	0.9	0
15	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	1.4	33
16	A discrete choice experiment investigating HIV testing preferences in South Africa. <i>Journal of Medical Economics</i> , 2022, 25, 481-490.	1.0	0
17	A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. <i>Archives of Osteoporosis</i> , 2022, 17, 57.	1.0	0
18	Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. <i>Journal of Medical Economics</i> , 2022, 25, 491-502.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model. <i>Epilepsia</i> , 2022, 63, 641-651.	2.6	6
20	Economic evaluation guidelines in low- and middle-income countries: a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e1.	0.2	11
21	Patients'™ and Psychologists'™ Preferences for Feedback Reports on Expected Mental Health Treatment Outcomes: A Discrete-Choice Experiment. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2022, 49, 707-721.	1.2	2
22	Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. <i>Osteoporosis International</i> , 2022, , 1.	1.3	3
23	The development process of economic evaluation guidelines in low- and middle-income countries: a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e35.	0.2	1
24	Global article collection: essential reads from around the world. <i>Journal of Medical Economics</i> , 2022, 25, 864-869.	1.0	1
25	A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service. <i>Journal of Medical Economics</i> , 2022, 25, 829-839.	1.0	2
26	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. <i>Pharmacoeconomics</i> , 2021, 39, 181-209.	1.7	63
27	The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best' Worst Scaling Experiment. <i>Pharmacoeconomics</i> , 2021, 39, 99-108.	1.7	3
28	Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of life. <i>Journal of Medical Economics</i> , 2021, 24, 54-60.	1.0	8
29	Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. <i>Osteoporosis International</i> , 2021, 32, 133-144.	1.3	9
30	Willingness to pay for primary health care at public facilities in the Western Cape Province, Cape Town, South Africa. <i>Journal of Medical Economics</i> , 2021, 24, 162-172.	1.0	5
31	Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e40.	0.2	15
32	Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 47.	1.2	54
33	Effective Risk Communication and Improving Adherence. , 2021, , 115-143.		1
34	Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. <i>Osteoporosis International</i> , 2021, 32, 595-606.	1.3	7
35	Using health-economic evidence to support policy-level decision-making in Singapore' sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. <i>Osteoporosis International</i> , 2021, 32, 787-789.	1.3	1
36	Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success. <i>Pharmacoeconomics</i> , 2021, 39, 433-446.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Expertsâ€™ preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1079-1083.	1.4	3
38	Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 579-593.	0.7	5
39	Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 123.	1.5	6
40	The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. <i>Osteoporosis International</i> , 2021, 32, 1517-1530.	1.3	51
41	Economic Burden of Multiple Sclerosis in Low- and Middleâ€™income Countries: A Systematic Review. <i>Pharmacoeconomics</i> , 2021, 39, 789-807.	1.7	27
42	Most Important Factors for Deciding Rehabilitation Provision for Severe Stroke Survivors Post Hospital Discharge: A Study Protocol for a Bestâ€™Worst Scaling Experiment. <i>Methods and Protocols</i> , 2021, 4, 27.	0.9	3
43	The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a bestâ€™worst scaling approach. <i>Journal of Medical Economics</i> , 2021, 24, 846-856.	1.0	2
44	Vaccine preferences driving vaccine-decision making of different target groups: a systematic review of choice-based experiments. <i>BMC Infectious Diseases</i> , 2021, 21, 879.	1.3	16
45	No consensus on cementless fixation currently being the most costâ€™effective mode of implant fixation in younger total hip arthroplasty patients. <i>International Journal of Clinical Practice</i> , 2021, 75, e14587.	0.8	0
46	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest groupâ€™. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 919-924.	1.6	7
47	Patientsâ€™ preferences for quality-of-life aspects in sarcopenia: a bestâ€™worst scaling study. <i>European Geriatric Medicine</i> , 2021, , 1.	1.2	0
48	Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. <i>Diabetes Care</i> , 2021, 44, 407-415.	4.3	12
49	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. <i>Scientific Reports</i> , 2021, 11, 19922.	1.6	32
50	Improvement of osteoporosis Care Organized by Nurses: ICON study - Protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 913.	0.8	8
51	The economic burden of the postoperative management in surgically treated trauma patients with peri- and/or intra-articular fractures of the lower extremities: A prospective multicenter cohort study. <i>Injury</i> , 2021, , .	0.7	0
52	Evidence-based recommendations for economic evaluations in spine surgery: study protocol for a Delphi consensus. <i>BMJ Open</i> , 2021, 11, e052988.	0.8	3
53	Quality of life and costs of patients prior to colorectal surgery. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 193-198.	0.7	8
54	Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 269-279.	0.7	11

#	ARTICLE	IF	CITATIONS
55	Preferences of people with Type 2 diabetes for diabetes care: a discrete choice experiment. <i>Diabetic Medicine</i> , 2020, 37, 1807-1815.	1.2	20
56	Understanding patients'™ preferences for osteoporosis treatment: the impact of patients'™ characteristics on subgroups and latent classes. <i>Osteoporosis International</i> , 2020, 31, 85-96.	1.3	8
57	Outcome Priorities for Older Persons With Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 267-271.e2.	1.2	13
58	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10â€“12, 2019, Hoofddorp, The Netherlands. <i>Neuromuscular Disorders</i> , 2020, 30, 93-103.	0.3	55
59	Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 284-286.	1.2	6
60	Early health economic modelling for a treatment candidate in hidradenitis suppurativa. <i>Journal of Medical Economics</i> , 2020, 23, 1516-1524.	1.0	4
61	A discrete-choice experiment to assess patients'™ preferences for osteoarthritis treatment: An ESCO working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 859-866.	1.6	7
62	Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments. <i>Vaccine</i> , 2020, 38, 7226-7238.	1.7	12
63	Understanding patients'™ preferences for HIV treatment among rural and urban Colombian patients. <i>Journal of Medical Economics</i> , 2020, 23, 801-802.	1.0	3
64	Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. <i>Medical Decision Making</i> , 2020, 40, 1003-1019.	1.2	7
65	Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. <i>The Cochrane Library</i> , 2020, 2020, CD008312.	1.5	13
66	Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews). <i>Journal of Clinical Epidemiology</i> , 2020, 128, 74-82.	2.4	15
67	A Digital Innovation for the Personalized Management of Adherence: Analysis of Strengths, Weaknesses, Opportunities, and Threats. <i>Frontiers in Medical Technology</i> , 2020, 2, 604183.	1.3	3
68	The clinical and economical impact of postoperative ileus in patients undergoing colorectal surgery. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13862.	1.6	25
69	The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments. <i>Current Medical Research and Opinion</i> , 2020, 36, 1257-1275.	0.9	16
70	Using statutory health insurance data to evaluate non-response in a cross-sectional study on depression among patients with diabetes in Germany. <i>International Journal of Epidemiology</i> , 2020, 49, 629-637.	0.9	9
71	Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 394-400.	1.6	14
72	Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study. <i>Diabetic Medicine</i> , 2020, 37, 1759-1765.	1.2	35

#	ARTICLE	IF	CITATIONS
73	Identification and expert panel rating of key structural approaches applied in health economic obesity models. <i>Health Policy and Technology</i> , 2020, 9, 314-322.	1.3	3
74	Patients'™ preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments. <i>Journal of Medical Economics</i> , 2020, 23, 546-556.	1.0	18
75	A discrete choice experiment to assess patients'™ preferences for HIV treatment in the rural population in Colombia. <i>Journal of Medical Economics</i> , 2020, 23, 803-811.	1.0	7
76	A discrete choice experiment to assess patients'™ preferences for HIV treatment in the urban population in Colombia. <i>Journal of Medical Economics</i> , 2020, 23, 812-818.	1.0	11
77	The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 334-335.	0.5	2
78	Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk. <i>Osteoporosis International</i> , 2020, 31, 1217-1229.	1.3	15
79	Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. <i>Osteoporosis International</i> , 2020, 31, 1645-1669.	1.3	49
80	Chinese patients'™ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment. <i>Archives of Osteoporosis</i> , 2019, 14, 85.	1.0	4
81	Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patients. <i>Current Medical Research and Opinion</i> , 2019, 35, 1859-1866.	0.9	6
82	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	1.3	69
83	Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. <i>Osteoporosis International</i> , 2019, 30, 649-658.	1.3	14
84	Exploring Women Healthcare Leaders' Perceptions on Barriers to Leadership in Greek Context. <i>Frontiers in Public Health</i> , 2019, 7, 68.	1.3	13
85	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Ageing Clinical and Experimental Research</i> , 2019, 31, 905-915.	1.4	47
86	Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 184-196.	1.6	30
87	Newborn screening for SMA in Southern Belgium. <i>Neuromuscular Disorders</i> , 2019, 29, 343-349.	0.3	65
88	Evidence-informed vaccine decision making: The introduction of Human Papilloma Virus (HPV) vaccination in the Netherlands. <i>Health Policy</i> , 2019, 123, 260-266.	1.4	4
89	A discrete-choice experiment to assess treatment modality preferences of patients with anxiety disorder. <i>Journal of Medical Economics</i> , 2019, 22, 169-177.	1.0	9
90	An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study). <i>Journal of Medical Economics</i> , 2019, 22, 238-244.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Pharmacoeconomic Analyses and Modeling. , 2019, , 261-275.		4
92	A discrete-choice experiment to assess treatment modality preferences of patients with depression. Journal of Medical Economics, 2019, 22, 178-186.	1.0	16
93	Patientsâ€™ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 2019, 31, 1-3.	1.4	23
94	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an expertsâ€™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57.	1.3	67
95	Comparison of statistical analysis methods for object case bestâ€ worst scaling. Journal of Medical Economics, 2019, 22, 509-515.	1.0	15
96	A discrete choice experiment to investigate patient preferences for HIV testing programs in BogotÃ¡, Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 195-201.	0.7	2
97	Relevance of barriers and facilitators in the use of health technology assessment in Colombia. Journal of Medical Economics, 2018, 21, 510-517.	1.0	6
98	OPTIMIZING USABILITY OF AN ECONOMIC DECISION SUPPORT TOOL: PROTOTYPE OF THE EQUIPT TOOL. International Journal of Technology Assessment in Health Care, 2018, 34, 68-77.	0.2	5
99	Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. Addiction, 2018, 113, 96-105.	1.7	7
100	Health-related quality of life and cost-effectiveness analysis of gum chewing in patients undergoing colorectal surgery: results of a randomized controlled trial. Acta Chirurgica Belgica, 2018, 118, 299-306.	0.2	6
101	Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 297-304.	0.7	12
102	Perioperative lipid-enriched enteral nutrition versus standard care in patients undergoing elective colorectal surgery (SANICS II): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 242-251.	3.7	28
103	Promoting the consumption of dairy products for fracture prevention: A good value for money?. Joint Bone Spine, 2018, 85, 403-404.	0.8	2
104	A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs. Epilepsy and Behavior, 2018, 79, 58-67.	0.9	14
105	Applying a best-worst scaling methodology to prioritise important attributes of counselling from community pharmacy usersâ€™ perspective, Saudi Arabia. Journal of Pharmaceutical Health Services Research, 2018, 9, 153-159.	0.3	2
106	The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 357-366.	1.6	22
107	Estimates of costs for modelling return on investment from smoking cessation interventions. Addiction, 2018, 113, 32-41.	1.7	9
108	Comparison of preferences of healthcare professionals and <scp>MS</scp> patients for attributes of diseaseâ€™modifying drugs: A bestâ€ worst scaling. Health Expectations, 2018, 21, 171-180.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 223-232.	0.7	10
110	The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 191-195.	0.7	6
111	Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. <i>Addiction</i> , 2018, 113, 7-18.	1.7	20
112	Using multi-criteria decision analysis to appraise orphan drugs: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 135-146.	0.7	18
113	Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2437-2447.	0.8	5
114	Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective. <i>PLoS ONE</i> , 2018, 13, e0205876.	1.1	0
115	EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTION. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 514-518.	0.2	9
116	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. <i>Frontiers in Endocrinology</i> , 2018, 9, 373.	1.5	249
117	Event simulation and external validation applied in published health economic models for obesity: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 529-541.	0.7	5
118	Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. <i>BMC Health Services Research</i> , 2018, 18, 115.	0.9	2
119	A best-worst scaling in Colombian patients to rank the characteristics of HIV/AIDS treatment. <i>Journal of Medical Economics</i> , 2018, 21, 468-473.	1.0	11
120	Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. <i>Rheumatology</i> , 2018, 57, 584-585.	0.9	3
121	Early intervention for subthreshold panic disorder in the Netherlands: A model-based economic evaluation from a societal perspective. <i>PLoS ONE</i> , 2018, 13, e0193338.	1.1	7
122	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017, 28, 767-774.	1.3	113
123	Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review. <i>Addiction</i> , 2017, 112, 946-967.	1.7	27
124	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.5	33
125	Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. <i>The Cochrane Library</i> , 2017, 2, CD008312.	1.5	37
126	Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 595-604.	4.6	90

#	ARTICLE	IF	CITATIONS
127	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. <i>Rheumatology</i> , 2017, 56, 1167-1176.	0.9	26
128	MOST IMPORTANT BARRIERS AND FACILITATORS REGARDING THE USE OF HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 183-191.	0.2	11
129	A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention. <i>Archives of Osteoporosis</i> , 2017, 12, 57.	1.0	15
130	Patients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments. <i>Patient</i> , 2017, 10, 553-565.	1.1	57
131	Effect of stage-based education provided by dedicated dietitians on hyperphosphataemic haemodialysis patients: results from the Nutrition Education for Management of Osteodystrophy randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 554-562.	1.3	8
132	Cost-effectiveness of interventions for treating anxiety disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2017, 210, 1-13.	2.0	48
133	EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 644-653.	0.2	7
134	A Cost-of-Illness Study of Patients with HIV/AIDS in Bogotá, Colombia. <i>Value in Health Regional Issues</i> , 2017, 14, 103-107.	0.5	4
135	Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. <i>Journal of Medical Economics</i> , 2017, 20, 1024-1038.	1.0	7
136	The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 303-310.	0.7	13
137	Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France. <i>Osteoporosis International</i> , 2017, 28, 833-840.	1.3	19
138	Comparing Analytic Hierarchy Process and Discrete-Choice Experiment to Elicit Patient Preferences for Treatment Characteristics in Age-Related Macular Degeneration. <i>Value in Health</i> , 2017, 20, 1166-1173.	0.1	21
139	Exploring consensus on how to measure smoking cessation. A Delphi study. <i>BMC Public Health</i> , 2017, 17, 890.	1.2	70
140	Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients. <i>Journal of Medical Internet Research</i> , 2017, 19, e249.	2.1	9
141	Identification and Prioritization of the Economic Impacts of Vaccines. <i>BioMed Research International</i> , 2016, 2016, 1-8.	0.9	2
142	Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. <i>Patient Preference and Adherence</i> , 2016, 10, 993.	0.8	16
143	Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. <i>Health Research Policy and Systems</i> , 2016, 14, 38.	1.1	19
144	Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling. <i>PLoS ONE</i> , 2016, 11, e0164862.	1.1	30

#	ARTICLE	IF	CITATIONS
145	A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 268-279.	1.1	130
146	A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. <i>European Journal of Public Health</i> , 2016, 27, ckw237.	0.1	8
147	How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 689-704.	0.7	134
148	Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. <i>Osteoporosis International</i> , 2016, 27, 2697-2707.	1.3	4
149	Risk of bias in model-based economic evaluations: the ECOBIAS checklist. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 513-523.	0.7	54
150	Systematic review and overview of health economic evaluation models in obesity prevention and therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 561-570.	0.7	17
151	Using Best-Worst Scaling to Investigate Preferences in Health Care. <i>Pharmacoeconomics</i> , 2016, 34, 1195-1209.	1.7	164
152	Health-Related Quality of Life of Patients with HIV/AIDS in Bogotá, Colombia. <i>Value in Health Regional Issues</i> , 2016, 11, 68-72.	0.5	21
153	Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. <i>Osteoporosis International</i> , 2016, 27, 301-308.	1.3	33
154	How Well Can Analytic Hierarchy Process be Used to Elicit Individual Preferences? Insights from a Survey in Patients Suffering from Age-Related Macular Degeneration. <i>Patient</i> , 2016, 9, 481-492.	1.1	19
155	The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2016, 27, 2489-2496.	1.3	12
156	A societal cost-of-illness study of hemodialysis in Lebanon. <i>Journal of Medical Economics</i> , 2016, 19, 1157-1166.	1.0	13
157	Focus Groups in Elderly Ophthalmologic Patients: Setting the Stage for Quantitative Preference Elicitation. <i>Patient</i> , 2016, 9, 47-57.	1.1	15
158	Understanding the stakeholders' intention to use economic decision-support tools: A cross-sectional study with the tobacco return on investment tool. <i>Health Policy</i> , 2016, 120, 46-54.	1.4	23
159	Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review. <i>Nephrology</i> , 2016, 21, 178-187.	0.7	17
160	Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. <i>Archives of Public Health</i> , 2015, 73, 48.	1.0	24
161	The effects of stimulation of the autonomic nervous system via perioperative nutrition on postoperative ileus and anastomotic leakage following colorectal surgery (SANICS II trial): a study protocol for a double-blind randomized controlled trial. <i>Trials</i> , 2015, 16, 20.	0.7	13
162	A Review of Patient Preferences for Osteoporosis Drug Treatment. <i>Current Rheumatology Reports</i> , 2015, 17, 61.	2.1	35

#	ARTICLE	IF	CITATIONS
163	Risk of bias in trial-based economic evaluations: Identification of sources and bias-reducing strategies. <i>Psychology and Health</i> , 2015, 30, 52-71.	1.2	41
164	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. <i>Pharmacoeconomics</i> , 2015, 33, 205-224.	1.7	84
165	Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. <i>European Journal of Public Health</i> , 2015, 25, 20-25.	0.1	41
166	The need for (cost)-effective interventions to enhance adherence with osteoporosis medications. <i>Current Medical Research and Opinion</i> , 2014, 30, 297-299.	0.9	1
167	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	1.6	29
168	Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. <i>Arthritis Research and Therapy</i> , 2014, 16, R36.	1.6	44
169	Management of osteoporosis of the oldest old. <i>Osteoporosis International</i> , 2014, 25, 2507-2529.	1.3	71
170	Eliciting patients' preferences for epilepsy diagnostics: A discrete choice experiment. <i>Epilepsy and Behavior</i> , 2014, 31, 102-109.	0.9	14
171	The application of health technology assessment in osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 895-910.	2.2	16
172	Analysis of a Small Group of Stakeholders Regarding Advancing Health Technology Assessment in India. <i>Value in Health Regional Issues</i> , 2014, 3, 167-171.	0.5	9
173	Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. <i>Osteoporosis International</i> , 2013, 24, 2291-2300.	1.3	10
174	Health Technology Assessment in Osteoporosis. <i>Calcified Tissue International</i> , 2013, 93, 1-14.	1.5	39
175	Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. <i>Osteoporosis International</i> , 2013, 24, 2907-2918.	1.3	75
176	Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 19-28.	0.7	18
177	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 303-313.	1.6	239
178	Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 807-815.	3.1	9
179	Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. <i>Patient Preference and Adherence</i> , 2013, 7, 133.	0.8	87
180	The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 159-166.	0.7	48

#	ARTICLE	IF	CITATIONS
181	The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland. <i>Value in Health</i> , 2012, 15, 604-612.	0.1	52
182	Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000â€“2007). <i>Arthritis Care and Research</i> , 2012, 64, 744-750.	1.5	37
183	A reappraisal of generic bisphosphonates in osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 213-221.	1.3	62
184	PMS39 MOST EFFECTIVE ADHERENCE-ENHANCING INTERVENTIONS FOR OSTEOPOROSIS MEDICATIONS. <i>Value in Health</i> , 2011, 14, A130.	0.1	2
185	Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium. <i>Pharmacoeconomics</i> , 2011, 29, 895-911.	1.7	61
186	A FRAXÂ® model for the assessment of fracture probability in Belgium. <i>Osteoporosis International</i> , 2011, 22, 453-461.	1.3	53
187	Partial adherence: a new perspective on health economic assessment in osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 2565-2573.	1.3	55
188	Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. <i>Calcified Tissue International</i> , 2010, 86, 202-210.	1.5	77
189	Costâ€“Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. <i>Value in Health</i> , 2010, 13, 394-401.	0.1	54
190	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. <i>International Journal of Clinical Practice</i> , 2010, 64, 756-762.	0.8	32
191	Costâ€“effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 359-366.	0.7	9
192	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. <i>Health Policy</i> , 2010, 96, 170-177.	1.4	56
193	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75Â¥years. <i>Bone</i> , 2010, 46, 440-446.	1.4	23
194	Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. <i>Bone</i> , 2010, 47, 34-40.	1.4	37
195	Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. <i>Osteoporosis International</i> , 2010, 21, 157-165.	1.3	25
196	PMS40 COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN. <i>Value in Health</i> , 2010, 13, A309-A310.	0.1	1
197	Potential clinical and economic impact of nonadherence with osteoporosis medications. <i>Calcified Tissue International</i> , 2010, 86, 202-10.	1.5	10
198	Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. <i>Journal of Medical Economics</i> , 2009, 12, 356-360.	1.0	11

#	ARTICLE	IF	CITATIONS
199	Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. <i>Value in Health</i> , 2009, 12, 687-696.	0.1	69
200	Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature. <i>Calcified Tissue International</i> , 2008, 82, 288-292.	1.5	75
201	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. <i>Disease Management and Health Outcomes</i> , 2008, 16, 429-438.	0.3	10
202	Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. <i>Bone</i> , 2008, 43, 991-994.	1.4	36
203	Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity. <i>Pharmacoeconomics</i> , 0, , .	1.7	0